NRG-LU008

Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer

Principal Investigator

Charles B. Simone II, MD,

Status

Open to Accrual

Disease Site

Lung [LU]

Non-small Cell Lung Cancer

Phase

III

Developmental Therapeutics

No

Primary Objective

• To compare the overall survival in patients with stage II-IIIC inoperable node-positive non-small cell lung cancer (NSCLC) after image guided, motion-managed conventional radiotherapy to the primary tumor and nodal metastases (Arm 1) or after image guided, motion-managed stereotactic body radiation therapy (SBRT) to the primary tumor followed by conventionally fractionated radiotherapy to nodal metastases (Arm 2) both given with concurrent platinum-based chemotherapy.
• To compare progression-free survival between the experimental arm (Arm 2) and control arm (Arm 1).

Patient Population

Pathologically(histologically or cytologically) proven diagnosis of Stage II or III (AJCCEighth Edition) non-small cell lung cancer (NSCLC) with known PD-L1 status priorto registration.

Target Accrual

474